Hinova Pharmaceuticals Inc. has patented new molecular glue degraders comprising E3 ubiquitin-protein ligase binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. As such, they are reported to be potentially useful for the treatment of autoimmune diseases, inflammatory disorders and cancer.